Stomach NeoplasmsPhase 2NCT00384878
Study of Cetuximab Plus P-HDFL for the First-Line Treatment of Advanced Gastric Cancer
A Phase 2 study testing Cetuximab, Cisplatin,5-Fluorouracil,Leucovorin in people with Stomach Neoplasms, run by Far Eastern Memorial Hospital at 1 site in Taiwan.
Trial summary
The primary end point of the study is confirmed objective response rate (complete response [CR] and partial response [PR]). A response rate of 80 percent for cetuximab plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin (P-HDFL) chemotherapy is assumed. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Stomach Neoplasms
- What is being tested?
- Cetuximab, Cisplatin,5-Fluorouracil,Leucovorin
- How many people
- 35 participants
- Where
- 1 siteTaiwan
- Study dates
- Jun 2006to Mar 2007
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 18 to 75 years
- Histologically proven adenocarcinoma of the stomach that is nonresectable, locally advanced, or recurrent/metastatic
- At least one measurable lesion (by RECIST, Response Evaluation Criteria in Solid Tumors), and no prior radiotherapy to the target measurable lesion
- No prior chemotherapy for gastric cancer, but post-gastrectomy adjuvant therapy with low-dose 5-FU [e.g., 5-FU 450 mg/m2 per week] completed more than 6 months before study enrollment is acceptable
- World Health Organization (WHO) performance status 2
- Adequate baseline organ functions (checked within one week before entry into this study), defined as WBC count 3,000 cells/µL with neutrophils ≥ 1,500 cells/µL, platelet count 100,000 cells/µL, hemoglobin 9 g/dL, serum total bilirubin level 1.5 X UNLs (upper normal limits), serum AST and ALT 2.5 X ULNs (or serum AST and ALT 5.0 X ULNs for patients with liver metastases), serum creatinine level 1.5 X UNLs, 24-hour urine CCr 60 ml/min
Show all 10Show fewer
- Fasting serum triglyceride level > 70 mg/dL, which should be checked within one week before entry into this study. The lower limit for fasting serum triglyceride (70 mg/dL) is set to avoid HDFL-related hyperammonemic encephalopathy, which occurs in around 5% of Taiwanese patients.
- Written informed consent
- At least one month from gastrectomy, in case gastrectomy was performed; at least 2 weeks from laparotomy without resection, in case laparotomy was performed to document nonresectable status
- Availability of tumor sample for retrospective testing of EGFR (pharmacogenomic mutation analysis and immunohistochemical staining).
Who cannot join
- Concomitant anti-cancer biological agents, chemotherapy, or radiotherapy other than indicated in this protocol
- CNS metastasis
- Pregnant women, breast-feeding women, and women of child-bearing potential or fertile men without adequate contraception
- Life expectancy less than 3 months
- Serious concomitant illness or significant dysfunction of major organ systems which prohibit chemotherapy, such as:
- symptomatic heart disease, including significant arrhythmias, congestive heart failure or myocardial infarction within 12 months.
Show all 14Show fewer
- extensive liver disease.
- major active infection.
- severe symptomatic pulmonary disease.
- Concurrent or prior second malignancy (except curatively resected cervical carcinoma in situ or squamous cell carcinoma of skin).
- Known hypersensitivity reaction to any of the components of study treatments.
- Medical or psychological conditions that would not permit the patient to complete the study or sign informed consent
- Significant diseases, in the investigator's opinion, which would exclude the patient from the study.
- Legal incapacity or limited legal capacity.
Trial locations and contacts
1 site in 1 country.
Taiwan1 site, 1 recruiting
- Recruiting
Kun Huei Yeh, Ph.D
Taipei, Ban-Ciao, 220
Kun Huei Yeh, Ph.D., 886-2-89667000 ext. 1611, khyeh@mail.femh.org.tw
About this study
Official title: A Phase II Study of Cetuximab Plus P-HDFL (Cisplatin and Weekly 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin) for the First-Line Treatment of Advanced Gastric Cancer
The primary end point of the study is confirmed objective response rate (complete response [CR] and partial response [PR]). A response rate of 80 percent for cetuximab plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin (P-HDFL) chemotherapy is assumed. The Simon two-stage design will be used for P1 - P0 = 0.20. The response rates of interest are P0 = 60% and P1 = 80%. The investigators will reject cetuximab plus P-HDFL chemotherapy if the response rate is 8/13 at the first stage, and will reject the cetuximab plus P-HDFL chemotherapy if the response rate is 25/35 at the second stage. If there are more than 8 responses in 13 patients in the first stage, the study will continue to a total of 35 patients in the second stage. If there are more than 25 responses in 35 patients in the second stage, this treatment will be acceptable with a p-value of 0.05 and of 0.20. Evaluable patients for response will be those who received at least 4 doses of cetuximab (i.e. one cycle of protocol treatment). All enrolled patients will be subjected to toxicity evaluations.
The primary end point of the study is confirmed objective response rates (by RECIST, Response Evaluation Criteria in Solid Tumors). The secondary end points of the study are progression-free survival, overall survival, and treatment-related toxicities.
The analysis of response to treatment will be restricted to the eligible patients with at least one measurable lesion. The safety analysis will be restricted to the patients who received at least one cycle of the administered chemotherapy. The time-to-event end points will be estimated using the method of Kaplan and Meier and based on the intent-to-treat principle. Overall survival will be defined as the time interval between the date of study entry and the date of death. Progression-free survival will be defined as the time interval between the date of study entry and the date of disease progression or death, whichever occurred first. Duration of response will be defined as the time interval between the date of initial objective response and the date of disease progression, which is only for responders. If the event is not yet observed at the time of the last record, the patient will be censored at that time point.
Read the detailed description
Non-resectable gastric cancer is an incurable disease. Systemic chemotherapy confers prolongation of survival and improvement of quality of life. Regimens containing cisplatin and 5-fluorouracil (5-FU) are widely adopted in the world. A P-HDFL regimen, based primarily on weekly 24-hour infusion of cisplatin and high-dose 5-FU and leucovorin, is commonly used in Taiwan for patients with advanced gastric cancer; the overall response rate is around 60% (45%-76%, 95% C.I.), and the patients' compliance is excellent.
Expression of EGF and EGFR was detected in about 62.1% and 51.5% gastric cancer tissues, respectively. Tumors with simultaneous expression of EGF, TGF-alpha, EGFR and p185c-erbB-2 were associated with a high BrdU labeling index, rapid tumor growth, and an unfavorable outcome. Teramoto et al. have shown a dose-dependent growth inhibition of an anti-EGFR monoclonal antibody (MoAb 528) on EGFR-overexpressing human gastric cancer cells, both in vitro and in vivo. We have recently demonstrated that cetuximab is cytotoxic to human gastric cancer cells, and cetuximab has a chemo-sensitizing effect for cisplatin and 5-FU in human gastric cancer cells (Yeh et al, unpublished observation). We hypothesize that the combination of cetuximab with P-HDFL will further improve the efficacy of the latter on advanced gastric cancer.
This is a multi-center, prospective phase II trial. Patients with histologically proven nonresectable or recurrent/metastatic gastric adenocarcinoma, with at least one measurable lesion, no prior chemotherapy or radiotherapy, and adequate baseline organ functions will be eligible. Cetuximab (Erbitux; Merck, Germany) 400 mg/m2 will be given as an intravenous (IV) infusion, initially (i.e., day 1 of cycle 1); and then followed by weekly IV infusions of cetuximab 250 mg/m2 (i.e., days 8, 15, 22 of cycle 1, and days 1, 8, 15, 22 of cycle 2 and subsequent 28-day cycles). Cisplatin will be given as a 24-hour continuous IV infusion in a dose of 35 mg/m2/day, admixing with 5-FU 2,000 mg/m2 and leucovorin (folinic acid) 300 mg/m2, day 1 and day 8. A 24-hour continuous IV infusion of 5-FU 2,000 mg/m2 and leucovorin 300 mg/m2 will be given on day 15. The cycles will be repeated every 28 days, and the response evaluation will be performed every two cycles and at the end of protocol treatment. Confirmed objective response rate by RECIST (Response Evaluation Criteria in Solid Tumors) will be the primary end-point. Using the Simon two-stage design for phase II study (P1 - P0 = 0.20 with the response rates of interest being P0 = 60% and P1 = 80%), a total of 35 patients are planned to be enrolled in an estimated enrollment period of 12 to 18 months.
- Conditions
- Stomach Neoplasms
- Being tested
- Cetuximab, Cisplatin,5-Fluorouracil,Leucovorin
- Medical subject headings
- Stomach Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cetuximab, Cisplatin,5-Fluorouracil,LeucovorinDrug
What is being measured
The primary outcome is the main question the study is designed to answer.
The primary end point of the study is confirmed objective response rates (by RECIST, Response Evaluation Criteria in Solid Tumors).
Secondary outcomes (1)
The secondary end points of the study are progression-free survival, overall survival, and treatment-related toxicities.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Oct 2006 (estimated)
- Study startJun 2006
- Primary completionMar 2007
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Stomach NeoplasmsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 35 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Far Eastern Memorial Hospital
- Sponsor type
- University, hospital or other
- Investigators
- Kun Huei Yeh, Ph.D., Principal investigator, Far Eastern Memorial Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00384878
- Sponsor's protocol ID
- FEMH-95011
- Status last verified
- Jun 2006
- First submitted
- 4 Oct 2006
- Last updated
- 9 Feb 2009
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Feb 2009. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase II Study of Cetuximab Plus P-HDFL (Cisplatin and Weekly 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin) for the First-Line Treatment of Advanced Gastric Cancer
- ClinicalTrials.gov ID
- NCT00384878
- Acronym / sponsor ID
- FEMH-95011
- Conditions
- Stomach Neoplasms
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 35 participants (estimated)
- Lead sponsor
- Far Eastern Memorial HospitalUniversity, hospital or other
- Study start
- Jun 2006
- Primary completion
- Mar 2007 (actual)
- First posted
- 6 Oct 2006 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary end point of the study is confirmed objective response rate (complete response [CR] and partial response [PR]). A response rate of 80 percent for cetuximab plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin (P-HDFL) chemotherapy is assumed. The Simon two-stage design will be used for P1 - P0 = 0.20. The response rates of interest are P0 = 60% and P1 = 80%. The investigators will reject cetuximab plus P-HDFL chemotherapy if the response rate is 8/13 at the first stage, and will reject the cetuximab plus P-HDFL chemotherapy if the response rate is 25/35 at the second stage. If there are more than 8 responses in 13 patients in the first stage, the study will continue to a total of 35 patients in the second stage. If there are more than 25 responses in 35 patients in the second stage, this treatment will be acceptable with a p-value of 0.05 and of 0.20. Evaluable patients for response will be those who received at least 4 doses of cetuximab (i.e. one cycle of protocol treatment). All enrolled patients will be subjected to toxicity evaluations.
The primary end point of the study is confirmed objective response rates (by RECIST, Response Evaluation Criteria in Solid Tumors). The secondary end points of the study are progression-free survival, overall survival, and treatment-related toxicities.
The analysis of response to treatment will be restricted to the eligible patients with at least one measurable lesion. The safety analysis will be restricted to the patients who received at least one cycle of the administered chemotherapy. The time-to-event end points will be estimated using the method of Kaplan and Meier and based on the intent-to-treat principle. Overall survival will be defined as the time interval between the date of study entry and the date of death. Progression-free survival will be defined as the time interval between the date of study entry and the date of disease progression or death, whichever occurred first. Duration of response will be defined as the time interval between the date of initial objective response and the date of disease progression, which is only for responders. If the event is not yet observed at the time of the last record, the patient will be censored at that time point.
Detailed description
Non-resectable gastric cancer is an incurable disease. Systemic chemotherapy confers prolongation of survival and improvement of quality of life. Regimens containing cisplatin and 5-fluorouracil (5-FU) are widely adopted in the world. A P-HDFL regimen, based primarily on weekly 24-hour infusion of cisplatin and high-dose 5-FU and leucovorin, is commonly used in Taiwan for patients with advanced gastric cancer; the overall response rate is around 60% (45%-76%, 95% C.I.), and the patients' compliance is excellent.
Expression of EGF and EGFR was detected in about 62.1% and 51.5% gastric cancer tissues, respectively. Tumors with simultaneous expression of EGF, TGF-alpha, EGFR and p185c-erbB-2 were associated with a high BrdU labeling index, rapid tumor growth, and an unfavorable outcome. Teramoto et al. have shown a dose-dependent growth inhibition of an anti-EGFR monoclonal antibody (MoAb 528) on EGFR-overexpressing human gastric cancer cells, both in vitro and in vivo. We have recently demonstrated that cetuximab is cytotoxic to human gastric cancer cells, and cetuximab has a chemo-sensitizing effect for cisplatin and 5-FU in human gastric cancer cells (Yeh et al, unpublished observation). We hypothesize that the combination of cetuximab with P-HDFL will further improve the efficacy of the latter on advanced gastric cancer.
This is a multi-center, prospective phase II trial. Patients with histologically proven nonresectable or recurrent/metastatic gastric adenocarcinoma, with at least one measurable lesion, no prior chemotherapy or radiotherapy, and adequate baseline organ functions will be eligible. Cetuximab (Erbitux; Merck, Germany) 400 mg/m2 will be given as an intravenous (IV) infusion, initially (i.e., day 1 of cycle 1); and then followed by weekly IV infusions of cetuximab 250 mg/m2 (i.e., days 8, 15, 22 of cycle 1, and days 1, 8, 15, 22 of cycle 2 and subsequent 28-day cycles). Cisplatin will be given as a 24-hour continuous IV infusion in a dose of 35 mg/m2/day, admixing with 5-FU 2,000 mg/m2 and leucovorin (folinic acid) 300 mg/m2, day 1 and day 8. A 24-hour continuous IV infusion of 5-FU 2,000 mg/m2 and leucovorin 300 mg/m2 will be given on day 15. The cycles will be repeated every 28 days, and the response evaluation will be performed every two cycles and at the end of protocol treatment. Confirmed objective response rate by RECIST (Response Evaluation Criteria in Solid Tumors) will be the primary end-point. Using the Simon two-stage design for phase II study (P1 - P0 = 0.20 with the response rates of interest being P0 = 60% and P1 = 80%), a total of 35 patients are planned to be enrolled in an estimated enrollment period of 12 to 18 months.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (10 listed)
- Age 18 to 75 years
- Histologically proven adenocarcinoma of the stomach that is nonresectable, locally advanced, or recurrent/metastatic
- At least one measurable lesion (by RECIST, Response Evaluation Criteria in Solid Tumors), and no prior radiotherapy to the target measurable lesion
- No prior chemotherapy for gastric cancer, but post-gastrectomy adjuvant therapy with low-dose 5-FU [e.g., 5-FU 450 mg/m2 per week] completed more than 6 months before study enrollment is acceptable
- World Health Organization (WHO) performance status 2
Key exclusion criteria (14 listed)
- Concomitant anti-cancer biological agents, chemotherapy, or radiotherapy other than indicated in this protocol
- CNS metastasis
- Pregnant women, breast-feeding women, and women of child-bearing potential or fertile men without adequate contraception
- Life expectancy less than 3 months
- Serious concomitant illness or significant dysfunction of major organ systems which prohibit chemotherapy, such as:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cetuximab, Cisplatin,5-Fluorouracil,Leucovorin | Drug | – |
Primary outcome
The primary end point of the study is confirmed objective response rates (by RECIST, Response Evaluation Criteria in Solid Tumors).
1 secondary outcome
The secondary end points of the study are progression-free survival, overall survival, and treatment-related toxicities.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Feb 2009.
Related trials for Stomach Neoplasms
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
Not yet recruitingPhase 1
GK01 Cell Therapy in Gastric Cancer With Peritoneal Metastasis
Gastric Cancer (GC)
RecruitingPhase 3
A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC.
Gastric, Esophagogastric Junction
Active, not recruitingEarly Phase 1
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
B-ALL, DLBCL
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Kun Huei Yeh, Ph.D. principal investigator
Far Eastern Memorial Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Cetuximab, Cisplatin,5-Fluorouracil,Leucovorin in people with Stomach Neoplasms, run by Far Eastern Memorial Hospital at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 9 Feb 2009. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Kun Huei Yeh, Ph.D. (886-2-89667000 ext. 1611, khyeh@mail.femh.org.tw), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The primary end point of the study is confirmed objective response rates (by RECIST, Response Evaluation Criteria in Solid Tumors).. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Feb 2009.